DermaXon received a Phase 1 STTR Grant funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases to support preclinical efficacy studies for a novel drug treatment for ichthyosis.
DermaXon a biotech company located in Missoula, Montana announced today a $215,000 Phase 1 Small Business Technology Transfer (STTR) award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. This award titled “Selective Inhibition of CYP26A1 in the Skin for the Treatment of Ichthyosis” provides critical support of a research project which examines the efficacy of DermaXon’s technology platform for the treatment of ichthyosis. This award has the potential to increase to $1.5 million, if the Phase 1 project is successful. The platform combines Cytochromes P450 (CYPs) inhibitors and gene expression profiling to identify more efficient and compliant treatments for skin diseases. DermaXon will compare the effect of approved and experimental drugs with their CYP26 inhibitors to mitigate hyperkeratosis associated with ichthyosis.
Ichthyosis is a family of life-threatening rare genetic disorders characterized by persistently dry and scaly skin. Current treatments do not adequately address patient needs, presenting significant efficacy or tolerability concerns. (For more information about ichthyosis: http://www.firstskinfoundation.org/ )
“We are excited to announce this award, which is an important step in our diligent ongoing efforts towards developing innovative rare skin disease treatments.” said Fanny Astruc-Diaz and Philippe Diaz, CEO and CSO of DermaXon.
About DermaXon: DermaXon is a Missoula-based drug discovery company providing first in-class drug candidates. DermaXon works to discover and develop novel therapeutic strategies to treat and prevent life-threatening skin diseases and neurodegenerative diseases. The company was founded in 2013 by Drs. Fanny Astruc-Diaz and Philippe Diaz, both Professors in the Department of Biomedical Sciences at the University of Montana. The company core technology was developed by Dr. Diaz at the University of Montana in collaboration with the University of Washington. DermaXon uses a novel drug screening strategy combining gene expression profiling, medicinal chemistry and, approved and experimental metalloprotein inhibitors to efficiently identify drug candidates to treat rare genetic skin diseases and neurodegenerative diseases.